Showing 2311-2320 of 2656 results for "".
- Jazz to Buy Cannabinoid Drugmaker GW Pharma in $7.2-Billion Dealhttps://modernod.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/Jazz Pharmaceuticals entered into a definitive agreement to acquire GW Pharmaceuticals for $220 per share, or a total consideration of $7.2 billion, adding the latter’s cannabinoid product platform, including Epidiolex (cannabidiol), to its neuroscience pipeline, the companies announced Wed
- Breakthrough by Moran Eye Center Scientist, Colleagues Fuels New Line of Disease Researchhttps://modernod.com/news/breakthrough-by-moran-eye-center-scientist-colleagues-fuels-new-line-of-disease-research/2478830/Scientists like the John A. Moran Eye Center’s Paul S. Bernstein, MD, PhD, know a special class of lipids, or fatty acids, found in the retina of the eye and in just a few other parts of the body play an important role in maintaining vision. But it’s been difficult to study whether giving
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- Avellino Exceeds 1 Million COVID-19 Tests in 2020 and Welcomes New Executive Team Hires In 2021https://modernod.com/news/avellino-exceeds-1-million-covid-19-tests-in-2020-and-welcomes-new-executive-team-hires-in-2021/2478756/Avellino Lab USA announced that the company performed over 1 million AvellinoCoV2 COVID-19 tests since March 2020, and has further expanded the company’s executive team to drive additional development and commercial growth in 2021. Chief Scientific Officer, Nazneen Aziz, PhD, and Global Head of S
- Biden Aims to Release All Available COVID-19 Vaccine Doses to Speed Up Distribution: Reporthttps://modernod.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/President-elect Joe Biden will seek to release nearly every available dose of the coronavirus vaccine when he takes office later this month, a move that signals a departure from the Trump administration and the FDA’s current stance of holding back half of the US vaccine supply in order to e
- Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for Investigational Dry AMD Treatmenthttps://modernod.com/news/gemini-therapeutics-announces-fda-fast-track-designation-granted-for-gem103-for-investigational-dry-amd-treatment/2478737/Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, has been granted Fast Track designation by the FDA. Gemini is evaluating GEM103, a recombinant, human complement factor H (CFH), for its ability to address the multiple AMD pathobiologies in gene
- Fewer New Cases of Intraocular Inflammation After First Year of Abicipar in AMD Patientshttps://modernod.com/news/fewer-new-cases-of-intraocular-inflammation-after-first-year-of-abicipar-in-amd-patients/2478703/Most cases of intraocular inflammation in patients with neovascular age-related macular degeneration (nAMD) who take AbbVie’s investigational drug abicipar pegol develop during the first year of treatment, according to a new report of two-year efficacy and safety results from a couple of pi
- Medmont Launches Meridia Advanced Topographerhttps://modernod.com/news/medmont-launches-meridia-advanced-topographer/2478664/Medmont International launched its next generation corneal topographer, the medmont meridia Advanced Topographer, in North America, Australia, and New Zealand. The medmont meridia extends E300’s topography performance by combining it with premium anterior and fluorescein imaging and videos
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea
- ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapyhttps://modernod.com/news/vigeneron-and-wuxi-advanced-therapies-enter-strategic-manufacturing-partnership-for-next-generation-ophthalmic-gene-therapy/2478606/ViGeneron and WuXi Advanced Therapies announced a partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s gene therapy pipeline addresses ophthalmic diseases with high unmet medical needs. Its lead pro